LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24BSX&src=ctag” target=”_blank”gt;$BSXlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June
24, 2019 deadline to file a lead plaintiff motion in the class
action filed on behalf of Boston Scientific Corporation (“Boston
Scientific” or the “Company”) (NYSE: BSX)
investors who purchased securities between February 26, 2015 and
April 16, 2019, inclusive (the “Class Period”).
If you are a shareholder who suffered a loss, click here to
participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.
On April 16, 2019, the Company was ordered by the U.S. Food and Drug
Administration (“FDA”) to stop selling and distributing its surgical
mesh products. According to the FDA, the Company had “not demonstrated a
reasonable assurance of safety and effectiveness for these devices.”
On this news, the Company’s share price fell $2.90 per share, more than
7%, over the following two trading sessions to close at $34.91 per share
on April 17, 2019, thereby injuring investors.
The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Boston Scientific’s
surgical mesh products indicated for the transvaginal repair of POP were
unsafe; (2) accordingly, Boston Scientific’s continued marketing and
sales of these devices in the United States was unlikely to be
sustainable; (3) separately, the Company had sold vaginal mesh implants
containing counterfeit or adulterated resin products imported from
China; (4) the foregoing conduct subjected the Company to a heightened
risk of regulatory scrutiny and/or government investigations; and (5) as
a result, the Company’s public statements were materially false and
misleading at all relevant times.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased or otherwise acquired Boston Scientific securities
during the Class Period you may move the Court no later than June
24, 2019 to request appointment as lead plaintiff in this putative
class action lawsuit. To be a member of the class action you need not
take any action at this time; you may retain counsel of your choice or
take no action and remain an absent member of the class action. If you
wish to learn more about this class action, or if you have any questions
concerning this announcement or your rights or interests with respect to
the pending class action lawsuit, please contact Lesley Portnoy,
Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles,
California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
[email protected]
www.glancylaw.com
